Lys05 NEW
| Price | $34 | $48 | $80 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-06 |
Product Details
| Product Name: Lys05 | CAS No.: 1391426-24-6 |
| Purity: 99.23% | Supply Ability: 10g |
| Release date: 2024/11/06 |
Product Introduction
Bioactivity
| 名稱 | Lys05 |
| 描述 | Lys05, or Lys01 trihydrochloride, is a potent, water soluble lysosomal autophagy inhibitor. Lys05 is a previously undescribed dimeric chloroquine which more potently accumulates in the lysosome and blocks autophagy compared with HCQ. Lys05 produced more potent antitumor activity as a single agent both in vitro and in vivo in multiple human cancer cell lines and xenograft models compared with HCQ. Lys05 is therefore a new lysosomal autophagy inhibitor that has potential to be developed further into a drug for cancer and other medical applications. |
| 細(xì)胞實(shí)驗(yàn) | 1205Lu, c8161, LN229 and HT-29 cells are treated with lys01 trihydrochloride (0, 0.01, 0.1, 1, and 10 μM) or Lys01 (0, 0.01, 0.1, 1, and 10 μM) in five replicates for 72 h. The Acid Phsophatase Assay kit is used for the MTT assay[1]. |
| 體外活性 | Lys01 is an autophagy inhibitor significantly (10-fold) more potent than hydroxychloroquine (HCQ). Its water-soluble derivative, Lys05, demonstrates enhanced potency by more effectively accumulating in and deacidifying lysosomes compared to HCQ. Both Lys01 and its trihydrochloride version induce similar dose-dependent effects, such as an increase in the LC3II/LC3I ratio, p62 protein accumulation, and identical half-maximal inhibitory concentrations (IC50) in the MTT assay[1]. |
| 體內(nèi)活性 | In a study utilizing high-dose, short-term administration of lys01 trihydrochloride at 76 mg/kg intraperitoneally (i.p.), no mortality was observed in mice. However, symptoms such as arched backs and lethargy became apparent after two days of treatment. Electron microscopy (EM) revealed that in lys01 trihydrochloride-treated tumors, cells maintained intact nuclear and cytoplasmic membranes but demonstrated a significant presence of large autophagic vacuoles (AVs). This treatment markedly inhibited tumor growth, showing a substantial 53% decrease in the average daily tumor growth rate compared to tumors in vehicle-treated control mice. Furthermore, a pronounced increase in AV accumulation was noted in treated tumors—three-fold in HCQ-treated and six-fold in lys01 trihydrochloride-treated tumors—after 14 days of treatment, when compared to control-treated tumors. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : 3 mg/mL (5.5 mM) DMSO : 5.5 mg/mL (10 mM), Sonication is recommended. |
| 關(guān)鍵字 | Inhibitor | Lys-05 | Autophagy | Lys05 | Lys01 Trihydrochloride | inhibit | Lys 05 | Lys01 |
| 相關(guān)產(chǎn)品 | Stavudine | Xylitol | Myricetin | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
| 相關(guān)庫 | 經(jīng)典已知活性庫 | 自噬庫 | 抑制劑庫 | NO PAINS 化合物庫 | 抗衰老化合物庫 | 已知活性化合物庫 | 抗癌化合物庫 | 抗COVID-19化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $150.00/100mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-04-17 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY